CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Has Average Price Target of $65.75 According to Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been given an average rating of “Moderate Buy” by the nineteen analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $69.69.

Several equities research analysts have recently commented on CRSP shares. Wells Fargo & Company lowered their target price on CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday. William Blair upgraded CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, October 9th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Tuesday.

CRISPR Therapeutics Price Performance

CRSP opened at $48.56 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.21 and a quick ratio of 17.85. The stock has a market capitalization of $4.71 billion, a P/E ratio of -10.24 and a beta of 1.92. The company’s 50 day simple moving average is $53.46 and its 200-day simple moving average is $52.82. CRISPR Therapeutics has a one year low of $44.12 and a one year high of $63.45.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The company had revenue of $12.67 million during the quarter, compared to the consensus estimate of $14.75 million. The business’s revenue was up 1311.1% on a year-over-year basis. Sell-side analysts anticipate that CRISPR Therapeutics will post -4.46 earnings per share for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 47,837 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the sale, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. The trade was a 13.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Simeon George sold 14,514 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $49.63, for a total transaction of $720,329.82. Following the sale, the director owned 15,486 shares of the company’s stock, valued at approximately $768,570.18. This represents a 48.38% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 93,558 shares of company stock valued at $4,881,663. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Choreo LLC grew its stake in shares of CRISPR Therapeutics by 3.4% during the third quarter. Choreo LLC now owns 7,539 shares of the company’s stock worth $417,000 after purchasing an additional 247 shares during the period. Sterling Capital Management LLC lifted its stake in CRISPR Therapeutics by 15.5% in the third quarter. Sterling Capital Management LLC now owns 1,934 shares of the company’s stock valued at $107,000 after buying an additional 260 shares during the period. Interchange Capital Partners LLC lifted its stake in CRISPR Therapeutics by 6.0% in the third quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company’s stock valued at $264,000 after buying an additional 268 shares during the period. Versant Capital Management Inc lifted its stake in CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after buying an additional 296 shares during the period. Finally, Sunbelt Securities Inc. boosted its holdings in CRISPR Therapeutics by 4.5% during the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company’s stock worth $373,000 after buying an additional 336 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Citigroup raised its price target to $90 from $88 and maintained a Buy rating. Needham also reaffirmed its Buy rating, reflecting continued analyst confidence. Citigroup price-target report Needham rating report
• Positive Sentiment: HC Wainwright and Brookline Capital Markets raised several estimates for future earnings, implying somewhat smaller projected losses in 2026–2027. HC Wainwright maintained its Buy rating. Analyst estimates
• Neutral Sentiment: The company will present clinical data from its investigational gene-edited CAR-T therapy zugo-cel in relapsed or refractory large B-cell lymphoma at the ASH meeting in December. The announcement creates a potential catalyst, but the results have not yet been reported. Zugo-cel clinical data announcement
• Negative Sentiment: CRISPR Therapeutics’ latest quarter missed analyst expectations for both earnings and revenue: EPS was a loss of $1.15 versus a $1.06 loss expected, and revenue was $12.67 million versus $14.75 million expected. CASGEVY revenue reached $99 million, but the double miss may be dampening investor sentiment. CRISPR Therapeutics Q3 2026 earnings analysis
• Negative Sentiment: RBC Capital assigned CRISPR Therapeutics a Hold rating, a more cautious counterpoint to the Buy ratings and raised target from other analysts. RBC Capital rating

About CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.